(GALDY) GALDERMA - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 47.606m USD | Total Return: 58.7% in 12m
Avg Turnover: 3.49M
Rev. Trend: 97.7%
Warnings
P/E ratio 78.1
Tailwinds
No distinct edge detected
Galderma Group AG is a Switzerland-based dermatology specialist providing a diverse portfolio across injectable aesthetics, consumer skincare, and therapeutic treatments. The company manages a range of established brands, including Cetaphil, Restylane, and Dysport, targeting both medical necessity and elective cosmetic procedures.
The specialty dermatology sector is characterized by high barriers to entry due to stringent regulatory requirements and the need for significant research and development investment. Galderma operates a vertically integrated business model, controlling the pipeline from laboratory science to clinical distribution across global markets.
For a deeper look into the companys valuation metrics and historical performance, you may want to consult ValueRay.
- Strong growth in injectable aesthetics portfolio drives premium segment revenue expansion
- Rising consumer demand for Cetaphil and dermatological skincare boosts global margins
- FDA approvals for Nemluvio and Relfydess catalyze new therapeutic revenue streams
- High sensitivity to discretionary consumer spending patterns impacts aesthetic treatment volume
- Strategic expansion in Chinese and emerging markets accelerates international sales growth
| Net Income: 613.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 5.99 > 1.0 |
| NWC/Revenue: 7.29% < 20% (prev 1.01%; Δ 6.28% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.19b > Net Income 613.0m |
| Net Debt (-632.0m) to EBITDA (1.20b): -0.53 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (234.6m) vs 12m ago -1.26% < -2% |
| Gross Margin: 68.86% > 18% (prev 0.69%; Δ 6.82k% > 0.5%) |
| Asset Turnover: 40.53% > 50% (prev 35.60%; Δ 4.92% > 0%) |
| Interest Coverage Ratio: 5.01 > 6 (EBITDA TTM 1.20b / Interest Expense TTM 175.0m) |
| A: 0.03 (Total Current Assets 2.44b - Total Current Liabilities 2.06b) / Total Assets 13.4b |
| B: 0.47 (Retained Earnings 6.35b / Total Assets 13.4b) |
| C: 0.07 (EBIT TTM 876.0m / Avg Total Assets 12.9b) |
| D: 1.21 (Book Value of Equity 6.35b / Total Liabilities 5.24b) |
| Altman-Z'' = 3.46 = A |
| DSRI: 1.20 (Receivables 893.0m/631.0m, Revenue 5.24b/4.44b) |
| GMI: 1.01 (GM 68.86% / 69.48%) |
| AQI: 0.92 (AQ_t 0.76 / AQ_t-1 0.83) |
| SGI: 1.18 (Revenue 5.24b / 4.44b) |
| TATA: -0.04 (NI 613.0m - CFO 1.19b) / TA 13.4b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 42.54 with a total of 19,607 shares traded.
Over the past week, the price has changed by +2.54%,
over one month by +5.03%,
over three months by +6.10% and
over the past year by +58.73%.
GALDERMA has no consensus analysts rating.
P/E Forward = 43.1034
P/S = 9.0833
P/B = 5.8412
P/EG = 1.835
Revenue TTM = 5.24b USD
EBIT TTM = 876.0m USD
EBITDA TTM = 1.20b USD
Long Term Debt = 2.58b USD (from longTermDebt, last quarter)
Short Term Debt = 27.0m USD (from shortLongTermDebt, last quarter)
Debt = 148.0m USD (Leases only: 148.0m)
Net Debt = -632.0m USD (calculated: Debt 148.0m - CCE 780.0m)
Enterprise Value = 47.0b USD (47.6b + Debt 148.0m - CCE 780.0m)
Interest Coverage Ratio = 5.01 (Ebit TTM 876.0m / Interest Expense TTM 175.0m)
EV/FCF = 45.56x (Enterprise Value 47.0b / FCF TTM 1.03b)
FCF Yield = 2.19% (FCF TTM 1.03b / Enterprise Value 47.0b)
FCF Margin = 19.67% (FCF TTM 1.03b / Revenue TTM 5.24b)
Net Margin = 11.70% (Net Income TTM 613.0m / Revenue TTM 5.24b)
Gross Margin = 68.86% ((Revenue TTM 5.24b - Cost of Revenue TTM 1.63b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.51 (Enterprise Value 47.0b / Total Assets 13.4b)
Interest Expense / Debt = 118.2% (Interest Expense 175.0m / Debt 148.0m)
Taxrate = 4.08% (26.0m / 638.0m)
NOPAT = 840.3m (EBIT 876.0m * (1 - 4.08%))
Current Ratio = 1.19 (Total Current Assets 2.44b / Total Current Liabilities 2.06b)
Debt / Equity = 0.02 (Debt 148.0m / totalStockholderEquity, last quarter 8.15b)
Debt / EBITDA = -0.53 (Net Debt -632.0m / EBITDA 1.20b)
Debt / FCF = -0.61 (Net Debt -632.0m / FCF TTM 1.03b)
Total Stockholder Equity = 7.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.74% (Net Income 613.0m / Total Assets 13.4b)
RoE = 7.83% (Net Income TTM 613.0m / Total Stockholder Equity 7.83b)
RoCE = 8.42% (EBIT 876.0m / Capital Employed (Equity 7.83b + L.T.Debt 2.58b))
RoIC = 7.42% (NOPAT 840.3m / Invested Capital 11.3b)
WACC = 9.14% (E(47.6b)/V(47.8b) * Re(9.17%) + (debt cost/tax rate unavailable))
Discount Rate = 9.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.87 | Cagr: -1.26%
[DCF] Terminal Value 75.45% ; FCFF base≈703.8m ; Y1≈806.8m ; Y5≈1.19b
[DCF] Fair Price = 13.91 (EV 15.7b - Net Debt -632.0m = Equity 16.3b / Shares 1.17b; r=9.14% [WACC]; 5y FCF grow 15.0% → 2.50% )
Revenue Correlation: 97.74 | Revenue CAGR: 12.83% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.51 | Chg30d=-2.64% | Revisions=-20% | GrowthEPS=+0.0% | GrowthRev=+21.8%
EPS next Year (2027-12-31): EPS=5.16 | Chg30d=-3.06% | Revisions=-20% | GrowthEPS=+47.2% | GrowthRev=+18.0%